ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

JCO Global Oncology is a premier open-access journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of high-quality research in the fields of cancer research and oncology. Since its inception in 2020, this journal has rapidly established itself as a vital resource for researchers, healthcare professionals, and students, holding a distinguished position in the Q2 category for both Cancer Research and Oncology based on the latest metrics. With an impressive Scopus rank of #61 out of 636 in General Medicine, the journal is recognized for its rigorous peer-reviewed articles and cutting-edge insights into oncological science. The open-access model ensures that vital research is readily available to a global audience, fostering collaborative advancements in the fight against cancer. JCO Global Oncology explores a broad range of topics and encourages submissions that contribute to the understanding, prevention, and treatment of various malignancies. With its substantial impact and ongoing contributions to the field, it stands as a promising platform for advancing oncological discourse and knowledge.

Asia-Pacific Journal of Oncology Nursing, published by Elsevier Science Inc, serves as a vital resource for researchers, practitioners, and students involved in the fields of oncology and nursing within the Asia-Pacific region. Since its transition to Open Access in 2014, the journal has aimed to disseminate cutting-edge research and innovative practices that enhance the quality of nursing care in oncology. With its ISSN 2347-5625 and E-ISSN 2349-6673, this journal holds a Q3 rank in both Oncology and Nursing (Oncology Nursing) as of 2023, reflecting its commitment to addressing current challenges and advancements in the discipline. With a Scopus ranking of 252/404 in Medicine (Oncology) and 13/20 in Nursing (Oncology Nursing), it occupies a crucial position in the academic landscape, nurturing knowledge that directly impacts patient care in oncology settings. Located at STE 800, 230 Park Ave, New York, NY 10169, the journal encourages contributions that explore multifaceted aspects of oncology nursing from 2018 to 2024, making it an important platform for emerging voices and established experts alike.

Gaceta Mexicana de Oncologia, published by the SOC MEXICANA ONCOLOGIA, A C, is a prominent Open Access journal that has contributed significantly to the field of oncology since its inception in 2002. With an ISSN of 1665-9201, this journal is dedicated to disseminating high-quality research pertaining to cancer studies, making it an essential resource for researchers, healthcare professionals, and students alike. Operating out of Spain, it serves as a platform for sharing innovative findings and clinical advancements in oncology. The journal's impact in the research community is reflected in its current rankings, placing it in the Q4 category for Cancer Research and Oncology fields. Despite its emerging status within the academic tiers, Gaceta Mexicana de Oncologia aims to enhance its presence in the scholarly domain, especially during its converged years from 2009 to 2024. The accessibility of its articles empowers a wider audience, fostering collaboration and knowledge-sharing necessary for combating cancer in diverse populations.

SUPPORTIVE CARE IN CANCER is a premier academic journal published by Springer, dedicated to advancing the understanding and management of supportive care for cancer patients. With a notable impact factor, the journal is recognized for its contribution to the fields of Oncology, Rehabilitation, and Nursing, achieving impressive rankings in Scopus, including Q1 for Oncology Nursing and Rehabilitation, and Q2 for general Oncology. Founded in 1993 and looking towards a promising future until 2024, it serves as a vital resource for researchers, professionals, and students engaged in these critical areas of healthcare. Although not an Open Access journal, its rigorous peer-reviewed articles provide valuable insights into innovative practices and evidence-based strategies that enhance patient quality of life during and after treatment. By bridging the gap between research and clinical practice, SUPPORTIVE CARE IN CANCER significantly influences patient outcomes and fosters interdisciplinary collaboration in patient support.

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Cancer Control is a prominent open-access journal published by SAGE Publications Inc, dedicated to advancing the field of oncology, hematology, and general medicine since its inception in 1995. With a focus on disseminating high-quality research, the journal contributes significantly to the knowledge base surrounding cancer prevention, treatment, and survivorship, making it a vital resource for researchers, healthcare professionals, and students alike. The journal currently holds a commendable position in the academic landscape, ranking in the Q2 category for both Hematology and Oncology, highlighting its impact and scholarly relevance. Available in an open-access format since 2018, Cancer Control ensures that critical findings are accessible to a broad audience, promoting collaboration and innovation in cancer-related research. Whether you're interested in the latest clinical trials, epidemiological studies, or public health initiatives, this journal serves as a key platform for sharing significant developments in cancer care and control.

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.